INTRODUCTION

Esthetic dermatology is an important branch of dermatology, which is being increasingly demanded by people all over the world. This includes procedures performed to rejuvenate the skin and other tissues of the body. The world of today is actually the world of cosmetic procedures. The increased awareness and interest of the world population about the cosmetic and esthetic medicine and the self-satisfaction induced by these interventions have been the causes of this increased demand. With introduction of minimally invasive procedures and less need to open surgical interventions, this enthusiasm has further increased. The most prevalent cosmetic interventions include botulinum toxin and dermal fillers injection. The coronavirus disease 2019 (COVID-19) pandemic has revolutionized every field of medicine. As every specialty has been affected by limitations caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this branch of medicine has also needed certain precautions for safer practice in the COVID era.

1 | INTRODUCTION

The COVID-19 pandemic and its impact on esthetic dermatology

Zeinab Aryanian MD1,2 | Amirhooshang Ehsani MD1,3 | Zahra Razavi MD1,3 | Shahin Hamzelou MD3 | Zeinab Mohseni Afshar MD4 | Parvaneh Hatami MD1

© 2022 Wiley Periodicals LLC.
psychological support in coronavirus days, when mental health may be disturbed.10

Here, we presented a comprehensive review on various aspects of association between esthetic medicine or cosmetic dermatology and COVID-19.

As mentioned above, any non-urgent surgery or dermatological procedures had been delayed or canceled in the beginning of the pandemic due to the fear of infection transmission. Most esthetic procedures necessitate close contact with the patients and this leads to increased risk of virus transmission.11 Although this virus does not transmit through skin contact and blood borne routes, most elective cosmetic procedures like resurfacing lasers and dermatological surgeries had been deferred due to the unknown issues about their safety.12 A considerable reduction in the number of minor cosmetic dermatological procedures like cryotherapy or filler injection was demonstrated in the beginning of the pandemic.13

In general, esthetic procedures are classified into three groups: noninvasive, minimally invasive, and invasive. Some examples of noninvasive procedures include cryolipolysis, laser lipolysis and electroporation. Botulinum toxin or filler injection, mesotherapy, microneedling, microblading, and carboxytherapy consist some of minimally invasive procedures; and liposuction, hair transplantation, and mechanical dermabrasion are invasive procedures. In the COVID era, the decision to undergo any procedure depends upon the degree of invasiveness, its urgency, and risk of viral transmission from the patient to the staff/clinician.2,14

2 | COSMETIC AND DERMATOLOGIC SURGERY

Perhaps, esthetic surgery has been the most commonly affected field of surgery in the COVID pandemic; being nonurgent and non-vital, these types of surgeries had been immediately canceled in the lockdown period15; on the other hand, due to the change in the life style of the world population, including the sedentary living, obesity had become an increasing reason for bariatric or liposuction surgeries and the demand for plastic surgery had increased.16 However, on a general consensus on timing of surgeries in the COVID-19 pandemic, except in few cases, elective surgeries of any specialty, including dermatologic surgery, had been canceled during the strict quarantine in the beginning of the pandemic. Biopsy or excision of benign lesions like lipomas and cysts had all been deferred. Even some oncosurgeries like melanoma and other skin malignancies had been postponed in a short period in which great fear of developing SARS-CoV-2 infection surrounded the world population. Plastic surgeons had prioritized more aggressive forms of skin cancers, including melanomas, ulcerated skin cancers with the risk of hemorrhage, and skin metastases for surgery in the beginning of the COVID pandemic.17,18

In those patients in need of urgent dermatologic or cosmetic surgery, COVID-19 infection should first be screened; only SARS-CoV-2 negative individuals are allowed to be operated.18-20

3 | PRECAUTIONS FOR DERMATOLOGIC AND ESTHETIC PROCEDURES IN THE COVID ERA

Cosmetic and esthetic procedures, like any other medical and surgical intervention, needs patient and health care personnel interaction; hence, the risk of SARS-CoV-2 transmission should always be considered and appropriate precautionary measures should be taken accordingly. These measures should follow general principles of COVID-19 prevention recommended by the World Health Organization (WHO).21 In general, any asymptomatic patient attending the esthetic clinic should be considered a SARS-CoV-2 carrier unless proved otherwise; therefore, COVID-19 testing should better be performed in all patients coming for esthetic procedures as an initial screening test.

In addition to the need to comply with hand hygiene protocols and sanitize all the equipment used during a procedure, appropriate precautions should also be applied in order to minimize the infection spread.22 Every procedure needs its own special attentions. Noninvasive procedures need basic protection, which include wearing N95 respirator mask and latex/nitrile gloves. Minimally invasive procedures require moderate-to-advanced protection for which goggles and gowns are added to the basic protection. However, some of the invasive procedures necessitate extreme protection with face-shield and head and shoe covers added to the previously mentioned personal protective equipment (PPE).23 The treatment area should have good ventilation. Windows should be opened after each procedure since SARS-CoV-2 survives up to 3 h in the air and opening the windows can disperse the infectious particles and decrease viral load of the surrounding environment. Negative pressure operating areas are recommended; however, these are better suited for surgical centers. It should be kept in mind that the risk of transmission is also higher in aerosol producing procedures and the ones with longer duration; hence, conversation between the clinician and the patient should be diminished; moreover, minimizing the duration of the procedures can also help in decreasing the risk of spread. However, viruses, including SARS-CoV-2 can survive up to 9 days on laser devices since they are made of stainless steel or have plastic handpieces, and this increases the risk of interpatients transmission; moreover, aerosolized particles are usually produced during some types of laser therapy, which harbors the risk of viral spread.10,14,24-26

In the lockdown or strict social distancing period, individuals who have undergone esthetic procedures can be followed by televisits, both for evaluating the outcome of the procedure and enquiring about developing SARS-CoV-2 symptoms.27

Diagnostic dermatological procedures such as dermatoscopy or skin biopsy should also be avoided in any patient with suspected or confirmed COVID-19, unless urgently required.28

Another important issue is the fact that few interactions between medical therapy of a COVID patient and esthetic procedures are identified; however, in COVID patients who are on immunosuppressive/immunomodulatory agents, invasive procedures should be deferred.29
4 | SARS-COV-2 INFECTION RELATED ADVERSE EVENTS IN INDIVIDUALS UNDERGOING COSMETIC PROCEDURES

In general, dermal fillers, which are used for aesthetic purposes, are produced with various formulations. Hyaluronic acid (HA) is a natural polysaccharide and the most commonly used tissue filler for dermal rejuvenation because of its better safety profile and the capability to be reversed by hyaluronidase enzymes. The HA technologies, per se, are various, each with different viscosity and duration of lasting. The ones with more viscosity and durability are more susceptible to develop inflammatory reactions.

As a matter of fact, SARS-CoV-2 infection has led to various dermatological reactions, which have included local to generalized cutaneous complications. Accordingly, with the universal increase in cosmetic and procedures, SARS-CoV-2 infection-associated reactions in body areas previously manipulated by dermatologists or plastic surgeons is an expectable issue. There have been several reports of cutaneous reactions in skin areas pretreated with cosmetic material. Induration, edema, tenderness, erythema, discoloration and nodule formation have been among the reported SARS-related reactions in the injection sites. However, dermatologic adverse events, such as granulomatous reaction and nodule formation, have been also reported following other aesthetic procedures like platelet-rich plasma (PRP)/fat injection. The underlying mechanism include the immunologic response to the viral spike protein and the resultant cutaneous reactions.

Despite bringing about much concern, most of the filler reactions following SARS-CoV-2 infection have been short-lasting and self-limiting. Therapeutic options that have been applied to control more prolonged or severe cases include antihistamines, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, angiotensin converting enzyme (ACE) inhibitors like Lisinopril, colchicine, 5-fluorouracil and methotrexate. In addition, hyaluronidase can be used to dissolve and reverse HA fillers. In rare instances, surgical interventions like curettage, incision, and drainage have been necessary.

5 | COVID VACCINE-RELATED ADVERSE EVENTS IN INDIVIDUALS UNDERGOING COSMETIC PROCEDURES

The introduction of COVID vaccines has given rise to several dermatologic complications, including new-onset or flare up of various dermatoses. Accordingly, the occurrence of vaccine-related adverse events was expected in body areas where esthetic procedures had been performed. Similar to COVID itself, COVID vaccination was also associated with dermatologic reactions in areas previously undergone tissue filler injection. These complications have included swelling, erythema and tenderness in the injected areas and lip angioedema. However, there have been rare reports of interaction between botulinum toxin and SARS-CoV-2 vaccination.

Not as common as filler injection site reactions, but reactions in body areas previously undergone cosmetic surgery has also been reported. Cosmetic breast augmentation is commonly performed in breast cancer patients who have undergone mastectomy. Moreover, capsular fibrosis and other aesthetic purposes are the reason of breast implant surgery. Acute onset of breast implant seroma has been demonstrated after receiving COVID vaccine, which was attributed to the postvaccination immune response.

These reactions are believed to be the result of vaccine adjuvants, which lead to autoimmune/inflammatory syndrome induced by adjuvants (ASIA); however, the interaction between the skin ACE-2 receptors and the vaccine’s spike protein can also be an underlying mechanism. Most of the vaccine-induced reactions in previously cosmetically manipulated areas are tardive reactions, which take place with delay, usually within 10 days after vaccination. However, these so-called adverse events have been reported even after 1 year of esthetic procedure. These adverse events may increase the hesitancy to get vaccinated against SARS-CoV-2; therefore, a dermatologist and an infectionist consultation is mandatory to assure the population of the temporary and self-limiting characteristic of these reactions and that these adverse events should never ban them from getting the second vaccine dose. The main strategy to prevent such reactions is to space enough time between vaccination and the planned dermatologic procedures; there is no consensus on the time span of safety; however, at least 3–4 weeks seems to be reasonable, with longer lag for those with a previous history of sensitivity to tissue fillers or those with autoimmune disorders or on immunosuppressive agents. Moreover, pretreating with antihistamines or corticosteroids can sometimes be beneficial in preventing vaccine-induced tissue filler reactions. Breast implant reactions after COVID-19 vaccination has been managed conservatively with NSAIDs, opioids, cryotherapy and sometimes implant removal and oral or parenteral antibiotics.

6 | CONCLUSION

Dermatologists and infectious diseases specialists have interacted greatly in the COVID pandemic, both because of the transmission risk of SARS-CoV-2 during cosmetic and esthetic procedures and also the adverse events associated with these procedures in individuals infected with or vaccinated against SARS-CoV-2. Therefore, dermatologists should apply to all precautionary measures in order to minimize the potential risks of viral transmission; furthermore, they should report and, if necessary, consult about any unusual reaction in pretreated areas of the body undergone cosmetic procedures in individuals with a history of SARS-CoV-2 infection or COVID-19 vaccination.

AUTHOR CONTRIBUTIONS

Parvaneh Hatami, Shahin Hamzelou, Amirhooshang Ehsani, and Zeinab Aryanian performed the research. Zeinab Mohseni Afshar and Zahra Razavi designed the research study. Amirhooshang Ehsani
and Parvaneh Hatami supervised the findings of this work. All authors discussed the results. Zeinab Mohseni Afshar wrote the initial draft. Shahin Hamzelou and Zeinab Aryanian wrote the revised version. All authors contributed to the preparation of data and finalization of this article.

ACKNOWLEDGMENT
The authors would like to thank Razi Hospital Clinical Research Development Center, Imam Reza Hospital Clinical Research Development Center and Autoimmune Bullous Diseases Research Center for their technical and editorial assistance.

FUNDING INFORMATION
We received no funding for this project.

CONFLICT OF INTEREST
All the authors declare that there is no conflict of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Parvaneh Hatami https://orcid.org/0000-0002-3531-2907

REFERENCES
1. Walker CE, Krumhuber EG, Dayan S, Furnham A. Effects of social media use on desire for cosmetic surgery among young women. Current Psychology. 2021;40(7):3355-3364.
2. Arora G, Arora S, Talathi A, et al. Safer practice of aesthetic dermatology during the COVID-19 pandemic: Recommendations by SIG aesthetics (IADVL academy). Indian Dermatol Online J. 2020;11(4):534-539.
3. Alhujayri AK, Alyousef LA, Alharthi SA, Aldekhayel S. Perception of cosmetic procedures among Saudis during COVID-19 pandemic. Plast Reconstr Surg Glob Open. 2021;9(6):e3710.
4. Liu W, Wei Z, Cheng X, Pang R, Zhang H, Li G. Public interest in cosmetic procedures during the COVID-19 pandemic: Infodemiology study of twitter data. J Med Internet Res. 2021;23(3):e23970.
5. Pikoos TD, Buzwell S, Sharp G, Rossell SL. The zoom effect: Exploring the impact of video calling on appearance dissatisfaction and interest in aesthetic treatment during the COVID-19 pandemic. Aesthet Surg J. 2021;41(2):NP2066-NP2075.
6. Kalantari Y, Aryanian Z, Mirahmadi SMS, Aililou S, Hatami P, Goodarzi A. A systematic review on COVID-19 vaccination and cosmetic filler reactions: A focus on case studies and original articles. J Cosmet Dermatol. 2022;21:15071.
7. Bachour Y, Bekkenk MW, Rustemeyer T, Kadouch JA. Late inflammatory reactions in patients with soft tissue fillers after SARS-CoV-2 infection and vaccination: A systematic review of the literature. J Cosmet Dermatol. 2022;21(4):1361-1368.
8. Rice SM, Siegel JA, Libby T, Graber E, Kourosh AS. Zooming into cosmetic procedures during the COVID-19 pandemic: The provider’s perspective. Int J Women’s Dermatol. 2021;7(2):213-216.
9. Ampuero D, Goldsworthy S, Delgado LE, Miranda JC. Using mental well-being impact assessment to understand factors influencing well-being after a disaster. Impact Assessment and Project Appraisal. 2015;33(3):184-194.
10. Türsen Ü, Türsen B, Lotti T. Aesthetic dermatology procedures in coronavirus days. J Cosmet Dermatol. 2020;19(8):1822-1825.
11. Kaye K, Paprottka F, Escudero R, et al. Elective, non-urgent procedures and aesthetic surgery in the wake of SARS–COVID-19: Considerations regarding safety, feasibility and impact on clinical management. Aesthetic Plast Surg. 2020;44(3):1014-1042.
12. Galadari H, Gupta A, Kroumpouzos G, et al. COVID 19 and its impact on cosmetic dermatology. Dermatol Ther. 2020;33:e13822.
13. Lee C-H. Role of dermatologists in the uprising of the novel corona virus (COVID-19): Perspectives and opportunities. Dermatologica Sinica. 2020;38(1):1.
14. Kapoor KM, Chatrath V, Boxley SG, et al. COVID-19 pandemic: Consensus guidelines for preferred practices in an aesthetic clinic. Dermatol Ther. 2020;33(4):e13597.
15. Brindle ME, Doherty G, Lillemoe K, Gawande A. Approaching surgical triage during theCOVID-19 pandemic. Ann Surg. 2020;272(2):e40-e42.
16. Jia P, Zhang L, Yu W, et al. Impact of COVID-19 lockdown on activity patterns and weight status among youths in China: The COVID-19 impact on lifestyle change survey (COINLICS). Int J Obes (Lond). 2021;45(3):695-699.
17. Geskin LJ, Trager MH, Aasi SZ, et al. Perspectives on the recommendations for skin cancer management during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(1):295-296.
18. Gentilesci S, Caretto AA, Tagliaferrri L, Salgarello M, Peris K. Skin cancer plastic surgery during the COVID-19 pandemic. Eur J Surg Oncol. 2020;46(6):1194-1195.
19. Rao GG, Agarwal A, Batura D. Testing times in coronavirus disease (COVID-19): A tale of two nations. Med J Armed Forces India. 2020;76(3):243-249.
20. Ng JN, Cembrano KG, Wanitphakdeedecha R, Manuskiatti W. The aftermath of COVID-19 in dermatology practice: What’s next? J Cosmet Dermatol. 2020;19(8):1826-1827.
21. Control CFD, Prevention. Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic. 2020.
22. Coccoli F, Perrone G, Chiarugi M, et al. Surgery in COVID-19 patients: Operational directives. World J Emerg Surg. 2020;15(1):25.
23. Organization WH. 2020 Rational Use of Personal Protective Equipment for COVID-19 and Considerations during Severe Shortages: Interim Guidance, 23 December 2020. World Health Organization.
24. Heinzerling A, Stuckey MJ, Scheuer T, et al. Transmission of COVID-19 to health care personnel during exposures to a hospitalized patient—Solano County, California, February 2020. Morb Mortal Wkly Rep. 2020;69(15):472-476.
25. Li Y, Duan S, Yu I, Wong T. Multi-zone modeling of probable SARS virus transmission by airflow between flats in block E Amoy Gardens. Indoor Air. 2005;15(2):96-111.
26. Garden JM, O’Bannon MK, Bakus AD, Olson C. Viral disease transmitted by laser-generated plume (aerosol). Arch Dermatol. 2002;138(10):1303-1307.
27. Bhargava S, McKeever C, Kroumpouzos G. Impact of COVID-19 pandemic on dermatology practices: results of a web-based, global survey. Int J Women’s Dermatol. 2021;7(2):217-223.
28. Fahmy DH, El-Amawy HS, El-Samongy MA, et al. COVID-19 and dermatology: A comprehensive guide for dermatologists. J Eur Acad Dermatol Venereol. 2020;34(7):1388-1394.
29. Der Sarkissian SA, Kim L, Veness M, Iyasemides E, Sebaratnam DF. Recommendations on dermatologic surgery during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(1):e29-e30.
30. Stefura T, Kacprzyk A, Dros J, et al. Tissue fillers for the nasolabial fold area: A systematic review and meta-analysis of randomized clinical trials. Aesthetic Plast Surg. 2021;45(5):2300-2316.
31. Mohseni Afshar Z, Babazadeh A, Hasanpour A, et al. Dermatological manifestations associated with COVID-19: A comprehensive review of the current knowledge. J Med Virol. 2021;93(10):5756-5767.
32. Mohaghegh F, Hatami P, Refaghat A, et al. New-onset pemphigus foliaceus following SARS-CoV-2 infection and unmasking multiple sclerosis: A case report. *Clin Case Rep*. 2022;10(6):e05910.

33. Afshar ZM, Miladi R, Janbakhsh A, Babazadeh A, Aryanian Z, Ebrahimpour S. Unmasking pustular psoriasis subsequent to COVID-19. *Journal of Pakistan Association of Dermatologists*. 2021;31(3):526-529.

34. Rowland-Warmann M. Hypersensitivity reaction to hyaluronic acid dermal filler following novel coronavirus infection—a case report. *J Cosmet Dermatol*. 2021;20(5):1557-1562.

35. Shome D, Doshi K, Vadera S, Kapoor R. Delayed hypersensitivity reaction to hyaluronic acid dermal filler post-COVID-19 viral infection. *J Cosmet Dermatol*. 2021;20(5):1549-1550.

36. Munavalli GG, Guthridge R, Knutsen-Larson S, Brodsky A, Matthew E, Landau M. COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: A challenging clinical conundrum in diagnosis and treatment. *Arch Dermatol Res*. 2022;314:1-15.

37. Incel Uysal P, Gunhan O. Granulomatous reaction at PRP/fat injection sites after recovering from SARS-CoV-2: A case report. *J Cosmet Dermatol*. 2022;21(2):426-428.

38. Munavalli GG, Knutsen-Larson S, Lupo MP, Geronemus RG. Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination—a model for inhibition of angiotensin II–induced cutaneous inflammation. *JAAD Case Rep*. 2021;10:63-68.

39. Philibert F, Gras-Champel V, Chaby G, Plantier F, Cartier H, Cogrel O, et al. Granulomes après injection d’Ellansé®, résolutifs sous méthotrexate. Annales de Dermatologie et de Vénéréologie; Elsevier.

40. Aguilera SB, Aristizabal M, Reed A. Successful treatment of calcium hydroxylapatite nodules with intralesional 5-fluorouracil, dexamethasone, and triamcinolone. *J Drugs Dermatol*. 2016;15(9):1142-1143.

41. Babazadeh A, Miladi R, Barary M, et al. COVID-19 vaccine-related new-onset lichen planus. *Clin Case Rep*. 2022;10(2):e05323.

42. Aryanian Z, Balighi K, Hatami P, Tootoonchi NM, Goodarzi A, Mohseni AZ. Morphea in two patients after being infected to and being vaccinated against SARS-CoV-2 infection. *Clin Case Rep*. 2022;10(4):e05667.

43. Michon A. Hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID-19 vaccination—a case report. *J Cosmet Dermatol*. 2021;20(9):2684-2690.

44. Osmond A, Kenny B. Reaction to dermal filler following COVID-19 vaccination. *J Cosmet Dermatol*. 2021;20(12):3751-3752.

45. Savva D, Battinetti G, Amenta F, Nittari G. Hypersensitivity reaction to hyaluronic acid dermal filler after the Pfizer vaccination against SARS-CoV-2. *Int J Infect Dis*. 2021;113:233-235.

46. Kalantari Y, Sadeghzadeh-Bazargan A, Aryanian Z, Hatami P, Goodarzi A. First reported case of delayed-type hypersensitivity reaction to non-hyaluronic acid polycaprolactone dermal filler following COVID-19 vaccination: A case report and a review of the literature. *Clin Case Rep*. 2022;10(2):e05343.

47. Guo X, Li T, Wang Y, Jin X. Sub-acute hypersensitive reaction to botulinum toxin type a following Covid-19 vaccination: Case report and literature review. *Medicine*. 2021;100(49):e27787.

48. Kayser F, Fournneau H, Mazy OC, Mazy S. Breast implant se-roma: A SARS-CoV-2 mRNA vaccine side effect. *J Clin Ultrasound*. 2021;49(9):984-986.

49. Shoenfeld Y, Agmon-Levin N. ‘ASIA’–autoimmune/inflammatory syndrome induced by adjuvants. *J Autoimmun*. 2011;36(1):4-8.

50. Rauso R, Lo Giudice G, Zerbinati N, Nicoletti GF, Fragola R, Tartaro G. Adverse events following COVID-19 vaccine in patients previously injected with facial filler: Scoping review and case report. *Applied Sciences*. 2021;11(22):10888.

51. Weitgasser L, Mahrhofer M, Schoeller T. Potential immune re- sponse to breast implants after immunization with COVID-19 vac- cines. *Breast*. 2021;59:76-78.

How to cite this article: Aryanian Z, Ehsani A, Razavi Z, Hamzelou S, Mohseni Afshar Z, Hatami P. The COVID-19 pandemic and its impact on esthetic dermatology. *J Cosmet Dermatol*. 2022;21:6557-6561. doi: [10.1111/jocd.15386](https://doi.org/10.1111/jocd.15386)